Pharmaceutical

AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront

AbbVie will pay $48m in upfront costs and up to $665m in milestone payments to license OSE’s monoclonal antibody OSE-230.

Feb 28, 2024 - 18:00
AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront
AbbVie will pay $48m in upfront costs and up to $665m in milestone payments to license OSE’s monoclonal antibody OSE-230.
Read the original article

Tags:

Previous Article

EMA and FDA green-light MoonLake to advance IL-17 inhibitor

Next Article

Biogen discontinues Aduhelm to focus on Leqembi for Alzheimer’s disease

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA withdraws approval of controversial drug to prevent preterm births

STAT+: FDA withdraws approval of controversial drug to ...

Apr 7, 2023

STAT+: Novartis reportedly decides to pass on Cytokinetics

STAT+: Novartis reportedly decides to pass on Cytokinetics

Jan 16, 2024

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA approval

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA ...

Aug 13, 2024